MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

Company Analysis - MoonLake Immunotherapeutics (NASDAQ: MLTX) is preparing to report results from its two Phase 3 studies, VELA-1 and VELA-2, which evaluate the efficacy of its drug sonelokimab for treating adults with moderate-to-severe conditions [2] Industry Insights - The Biotech Analysis Central service provides deep-dive analysis of pharmaceutical companies, offering a library of 600+ biotech investing articles and a model portfolio of 10+ small and mid-cap stocks with detailed analysis for each [2] - The service is available for $49 per month, with a yearly subscription offering a 33.50$399 per year [1]